A Phase 3 interventional study of otelixizumab infusion plus physician determined standard of care and placebo infusion plus physician determined standard of care in Diabetes Mellitus, Type 1, sponsored by GlaxoSmithKline. Completed at 109 sites in 9 countries. Open to participants aged 12 Years to 45 Years. Per ClinicalTrials.gov, last updated 2017-10-03.
Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment
The purpose of this study is to find out if an 8-day series of otelixizumab infusions leads to greater improvement in insulin secretion as compared with placebo infusion. Insulin secretion will be assessed using mixed meal-stimulated C-peptide.
Subjects will be assigned to receive either otelixizumab or placebo at a ratio of 2:1 (2/3 otelixizumab, 1/3 placebo). These study agents will be administered as an addition to insulin, diet, and other physician determined standard of care treatments.
DEFEND-1 is now closed to enrollment.
DEFEND-2 will begin early in 2010. It is very similar to DEFEND-1 and will again require subjects with new onset type 1 diabetes. Please check back here for more details.
In the meantime, established and new onset type 1 diabetes patients in North America are welcome to consider the TTEDD study:
http://www.clinicaltrials.gov/ct2/show/NCT00451321?term=TTEDD\&rank=1
The following visits are required:
10,925 studies on the registry are indexed under Diabetes Mellitus; 1,319 are open to participants now.
This study's enrollment of 272 is above the median of 80 across 8,367 interventional studies indexed under Diabetes Mellitus.
Browse Diabetes Mellitus studies →GlaxoSmithKline is the lead sponsor of 3,562 studies on the registry; 117 are open to participants now.
Of its 258 completed or terminated interventional studies of FDA-regulated products, 232 (90%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
otelixizumab
Biological: otelixizumab infusion plus physician determined standard of care
Placebo
Biological: placebo infusion plus physician determined standard of care
infusion
Also known as: monoclonal antibody, ChAglyCD3, anti-CD3, TRX4
infusion
Change From Baseline in 2-hour Mixed Meal Stimulated C-peptide Area Under Curve [AUC] (Normalized for 120-minute Time Interval) at Month 12
Mixed meal-stimulated C-peptide AUC was the area under the C-peptide/time curve from Time 0 to 120 minutes, calculated using the trapezoidal rule. This reported AUC was normalized for time interval by dividing it by 120 minutes. This normalized AUC was calculated for each participant at Baseline, Week 12, and at Months 6, 12, 18, and 24. Data has been presented for meal stimulated C-peptide Area under assessment performed at Month 12. Baseline assessments were carried out on the morning of Day 1, before the start of the first infusion of study drug. Change from Baseline was calculated by subtracting the Baseline value from the post-randomization value at Month 12.
Time frame: Baseline (0-120 minutes on Day 1) and Month 12 (0-120 minutes)
Number of Participants Who Were Responders for (Glycosylated Hemoglobin) HbA1c/Insulin Use Response at Week 12 and Months 6 and 12
A participant was considered a responder if, at the given time point, the participant had HbA1c\<= 6.5%, and mean daily insulin use over 7 consecutive days \< 0.5 international units per kilogram per day (IU/kg/day) during the 2 weeks preceding the visit. Data has been presented from number of participants with their percentages who were responders at Week 12 and Months 6 and 12.
Time frame: Week 12 and Months 6 and 12
Mean Daily Insulin Use at Week 12 and Months 6 and 12.
Participants recorded their daily insulin use in their electronic diaries. In particular, insulin was recorded thoroughly and accurately for at least 7 consecutive days during the 2 weeks before the visits at Baseline, Week 12, and Months 6 and 12. During each of these visits, the investigator/designee accessed the invivodata DiaryPRO web site to review insulin-use data for the previous 2-week period to ensure completeness. If errors/gaps were identified (e.g., if the participant did not take insulin and not entered 0 units), the investigator/designee recorded the missing data from participant recall using a data clarification form (DCF). Paper diary to collect insulin use, were reviewed for completeness. Any missing data that could be recalled by the participant was entered. If the participant did not record any insulin use during the 2-week period before the visit, the site obtained an insulin use history for the previous 7 days and calculated the average daily insulin dose.
Time frame: Week 12 and Months 6 and 12.
HbA1c Level at Week 12 and Months 6 and 12
HbA1c levels were recorded at Screening, Baseline (Day 1), Day 28, Week 8, Week 12, Months 4 to 12 and Month 24. Data has been presented for HbA1c levels at Week 12 and Months 6 and 12.
Time frame: Week 12 and Months 6 and 12
Number of Hypoglycemic Events Defined by Hypoglycemic Event Categories From Baseline Upto Month 12
Hypoglycemic events reported by participants were classified as defined by the American Diabetes Association (ADA) Workgroup on Hypoglycemia as follows: Severe hypoglycemia: an event requiring assistance of another person to actively administer carbohydrate, glucagon/other resuscitative actions, documented symptomatic hypoglycemia: an event during which typical symptoms of hypoglycemia are accompanied by a measured plasma glucose concentration(PGC)\<=70 mg/dL, asymptomatic hypoglycemia: an event not accompanied by typical symptoms of hypoglycemia but with a measured PGC\<=70 mg/dL,probable symptomatic hypoglycemia: an event during which symptoms of hypoglycemia are not accompanied by a plasma glucose determination, but were presumably caused by a PGC\<=70 mg/dL and relative hypoglycemia: an event during which the person with diabetes reports any of the typical symptoms of hypoglycemia, and interprets the symptoms as indicative of hypoglycemia, but with a measured PGC\>70 mg/dL.
Time frame: Upto Month 12
Number of Participants With Hypoglycemic Events Defined by Hypoglycemic Event Categories From Baseline Upto Month 12
Hypoglycemic events reported by participants were classified as defined by the ADA Workgroup on Hypoglycemia as Severe hypoglycemia: an event requiring assistance of another person to actively administer carbohydrate, glucagon/other resuscitative actions, documented symptomatic hypoglycemia: an event during which typical symptoms of hypoglycemia are accompanied by a measured plasma glucose concentration (PGC)\<=70 mg/dL, asymptomatic hypoglycemia: an event not accompanied by typical symptoms of hypoglycemia but with a measured PGC\<=70 mg/dL,probable symptomatic hypoglycemia: an event during which symptoms of hypoglycemia are not accompanied by a plasma glucose determination, but were presumably caused by a PGC\<=70 mg/dL and relative hypoglycemia: an event during which the person with diabetes reports any of the typical symptoms of hypoglycemia, and interprets the symptoms as indicative of hypoglycemia, but with a measured PGC\>70 mg/dL. Only categories with values are presented.
Time frame: Upto Month 12
Number of Hypoglycemic Excursions (<=70 mg/dL) With Most Complete Glucose at Week 12 and Months 6 and 12.
The event frequency of glucose measurements that were hypoglycemic excursions were calculated per participant basis, using the number of occurrences where blood glucose was less than or equal to 70 mg/dL. Most complete glucose interval was the 7 day period with the maximum number of days with at least 4 recordings per day. If these results were in more than one 7 day period, then the 7 day period with the largest average number of daily recordings (out of those with the maximum number of days with at least 4 recordings per day) was selected. If there were 2 or more 7 day periods that have the same number of days with at least 4 recordings and the same maximum average number of glucose recordings, the period that ended closest to the day of the study was selected.
Time frame: Week 12 and Months 6 and 12.
Magnitude of Greatest Hypoglycemic Excursions With Most Complete Glucose at Week 12 and Months 6 and 12.
The greatest hypoglycemic excursions during an interval was calculated as 70 mg/dL minus the lowest recorded glucose level in the interval. If a participant had data recorded during the interval but did not have a value below 70 mg/dL, the participants greatest hypoglycemic excursion for that interval was 0 mg/dL. Most complete glucose interval was the 7 day period with the maximum number of days with at least 4 recordings per day. If these results were in more than one 7 day period, then the 7 day period with the largest average number of daily recordings (out of those with the maximum number of days with at least 4 recordings per day) was selected. If there were 2 or more 7 day periods that have the same number of days with at least 4 recordings and the same maximum average number of glucose recordings, the period that ended closest to the day of the study was selected.
Time frame: Week 12 and Months 6 and 12.
Number of Participants With Hypoglycemic Excursions With Most Complete Glucose at Week 12 and Months 6 and 12
Percentage of hypoglycemic excursions was calculated as the total number of observations that exceed the hypoglycemic excursion boundary (i.e.\<= 70 mg/dL) divided by the total number of glucose measurements recorded in a time interval for the intervals: Baseline to Week 12, post-Week 12 to Month 6, post-Month 6 to Month 12. Most complete glucose interval was the 7 day period with the maximum number of days with at least 4 recordings per day. If these results were in more than one 7 day period, then the 7 day period with the largest average number of daily recordings (out of those with the maximum number of days with at least 4 recordings per day) was selected. If there were 2 or more 7 day periods that have the same number of days with at least 4 recordings and the same maximum average number of glucose recordings, the period that ended closest to the day of the study was selected. Data has been presented for number of participants with their percentages having hypoglycemic excursion.
Time frame: Week 12 and Months 6 and 12
Number of Hyperglycemic Excursions With Most Complete Glucose at Week 12 and Months 6 and 12.
The event frequency of glucose measurements that were hyperglycemic excursions were calculated on a per participant basis using the number of occurrences where blood glucose was greater than the hyperglycemic tolerance limit. There were 3 hyperglycemic tolerance limits considered: 200 mg/dL, 130 mg/dL and 100 mg/dL. Most complete glucose interval was the 7 day period with the maximum number of days with at least 4 recordings per day. If these results were in more than one 7 day period, then the 7 day period with the largest average number of daily recordings (out of those with the maximum number of days with at least 4 recordings per day) was selected. If there were 2 or more 7 day periods that have the same number of days with at least 4 recordings and the same maximum average number of glucose recordings, the period that ended closest to the day of the study was selected.
Time frame: Week 12 and Months 6 and 12
Magnitude of Greatest Hyperglycemic Excursions With Most Complete Glucose at Week 12 and Months 6 and 12.
The greatest hyperglycemic excursions during an interval was calculated as the largest recorded glucose level in the interval minus the hyperglycemic tolerance limit value (HGTLV). If a participant had data recorded during the interval but did not have a value above the HGTLV, the participants greatest hyperglycemic excursion for that interval was 0 mg/dL. Most complete glucose interval was the 7 day period with the maximum number of days with at least 4 recordings per day. If these results were in more than one 7 day period, then the 7 day period with the largest average number of daily recordings (out of those with the maximum number of days with at least 4 recordings per day) was selected. If there were 2 or more 7 day periods that have the same number of days with at least 4 recordings and the same maximum average number of glucose recordings, the period that ended closest to the day of the study was selected.
Time frame: Week 12 and Months 6 and 12.
Number of Participants With Hyperglycemic Excursions With Most Complete Glucose at Week 12 and Months 6 and 12
Percentage of hyperglycemic excursions was calculated as the total number of observations that exceed the hyperglycemic excursion boundary (i.e. \> HGTLV) divided by the total number of glucose measurements recorded in a time interval for the intervals: Baseline to Week 12, post-Week 12 to Month 6, post-Month 6 to Month 12. Most complete glucose interval was the 7 day period with the maximum number of days with at least 4 recordings per day. If these results were in more than one 7 day period, then the 7 day period with the largest average number of daily recordings (out of those with the maximum number of days with at least 4 recordings per day) was selected. If there were 2 or more 7 day periods that have the same number of days with at least 4 recordings and the same maximum average number of glucose recordings, the period that ended closest to the day of the study was selected. Data for number of participants with their percentages are presented.
Time frame: Week 12 and Months 6 and 12
Change From Baseline in Average Daily Risk Range (ADRR) at Week 12 and Months 6 and 12.
Average daily risk range is a measure for evaluation of blood glucose variability that was designed to be equally sensitive to hypoglycemia and hyperglycemia. The ADRR was assessed over 30-day periods prior to Baseline and at key visits Week 12 and Months 6 and 12. Baseline assessments were carried out on the morning of Day 1, before the start of the first infusion of study drug. Change from Baseline was calculated by subtracting the Baseline value from the post-randomization value at Week 12 and Months 6 and 12.
Time frame: Baseline (Day 1) and Week 12, Months 6 and 12.
Composite Rank Summary for HbA1c and Exogenous Insulin Use at Month 6 and Month 12
O'Brien mean rank analyses was performed on a two-part composite of the baseline-adjusted HbA1c level and the baseline-adjusted mean total daily insulin use per kg body weight in the otelixizumab group compared with the placebo group at Months 6, 12. For the O'Brien mean rank analysis at a particular time point, adjusted HbA1c values (for both treatment groups together) was ranked from smallest to largest, and adjusted mean daily insulin use values were ranked from smallest to largest. For each participant, the HbA1c and insulin use ranks were added together, producing a composite rank. A treatment comparison test was then performed on the composite ranks.
Time frame: Month 6 and 12
Composite Rank Summary for C-Peptide AUC, HbA1c and Exogenous Insulin Use at Month 6 and Month 12
O'Brien analyses will be performed on a three-part composite of HbA1c level, C-peptide AUC, and mean daily Insulin use in the otelixizumab group compared with the placebo group at Months 6 and12. For the O'Brien mean rank analysis at a particular time point, HbA1c and insulin use will be ranked from smallest to largest, and C-peptide AUC will be ranked from largest to smallest. For each participant, the C-Peptide AUC, ranks for HbA1c and insulin use were added together, producing a composite rank. A treatment comparison test was then performed on the composite ranks.
Time frame: Month 6 and 12
Change From Baseline in Level of Cytokines Interleukin (IL-6), IL-10 and Tumor Necrosis Factor-alpha (TNF-a) at Day 1, Day 4, Day 8
Levels of cytokine (TNFα, IL-6, IL-10) were measured at Baseline and at 2 hours after end of infusion (EOI) on Day 1, Day 4, Day 8 . Baseline assessments were carried out on the morning of Day 1, before the start of the first infusion of study drug. Change from Baseline was calculated by subtracting the Baseline value from the post-randomization value at Day 1, Day 4 and Day 8.
Time frame: Day 1, Day 4, Day 8
Percent Change From Baseline in Circulating Peripheral Lymphocytes CD4+CD25+FoxP3+ T Cells and CD4+CD25hiFoxP3+ T Cells in Type 1 Diabetes Mellitus (TIDM) up to Month 12
Blood samples were drawn for lymphocyte subset evaluations at Baseline and at 2hours after EOI on Day 4, pre-dose and after E0I on Day 8, Day 14, Day 21, Day 28, Week 6, Week 8, Week 10, Week 12, Month 6 and Month 12. Percentages of relevant lymphocyte subsets were determined by flow cytometry. The lymphocyte subsets assessed included CD8+CD25+ T lymphocytes, as well as the subsets of lymphocytes of these type that were positive for FoxP3, a protein that was expressed at high levels in the cytoplasm of regulatory T cells. CD4+CD25hiFoxP3+ T lymphocytes, a cell type was of interest because it played a regulatory role in T1DM. Baseline assessments were carried out on the morning of Day 1, before the start of the first infusion of study drug. Change from Baseline was calculated by subtracting the Baseline value from the post-randomization value at the time of assessment.
Time frame: Baseline (pre-dose on Day 1) and up to 12 Months
Percent Change From Baseline in Cell-bound Otelixizumab on CD4+ T Cells at Day 1, Day 4, Day 8
The amount of cell-bound otelixizumab was determined by flow cytometry. The extent of T cell receptor alpha beta (TCRαβ) expression was determined using an antibody that bound to TCRαβ but did not compete with otelixizumab for binding sites at the expected range of concentrations. The MESF of the anti-TCRαβ antibody was used to quantify the number of CD3/TCR complexes present on T cells. Free otelixizumab binding sites (sites not occupied by otelixizumab) were detected by staining with biotinylated otelixizumab. The MESF of bound biotinylated otelixizumab was directly proportional to the availability of free otelixizumab binding sites. MESF of bound antibody on CD4+ T cells was a direct measurement of cell-bound otelixizumab on CD4+ T cells. Baseline assessments were carried out on the morning of Day 1, before the start of the first infusion of study drug. Change from Baseline was calculated by subtracting the Baseline value from the post-randomization value at Day 1, Day 4 and Day 8.
Time frame: Baseline (pre-dose on Day 1), Day 4 and Day 8
Percent Change From Baseline in CD3/TCR Saturation on CD4+ T Cells and CD8+ T Cells at Day 1, Day 4, Day 8
The extent of saturation of CD3/TCR receptors on CD4+ and CD8+ lymphocytes was determined by flow cytometry. The extent of TCRαβ expression was determined using an antibody that bound to TCRαβ but did not compete with otelixizumab for binding sites at the expected range of concentrations. The MESF of the anti-TCRαβ antibody was used to quantify the number of CD3/TCR complexes present on T cells. The MESF of bound biotinylated otelixizumab was directly proportional to the availability of free otelixizumab binding sites. MESF of free CD3 sites on CD4+ T cells and CD8+ T cells was direct measurement of saturation of the CD3/TCR complex on CD4+ T cells and CD8+ T cells. Baseline assessments were carried out on the morning of Day 1, before the start of the first infusion of study drug. Change from Baseline was calculated by subtracting the Baseline value from the post-randomization value at Day 1, Day 4 and Day 8.
Time frame: Baseline (Pre-dose Day 1), Day 4, Day 8
Percent Change From Baseline in CD3/TCR Modulation on CD4+ T Cells and CD8+ T Cells at Day 1, Day 4, Day 8
The extent of modulation of CD3/TCR receptors on CD4+ and CD8+ lymphocytes was determined by flow cytometry. The extent of TCRαβ expression was determined using an antibody that bound to TCRαβ but did not compete with otelixizumab for binding sites at the expected range of concentrations. The MESF of the anti-TCRαβ antibody was used to quantify the number of CD3/TCR complexes present on T cells. The MESF of bound biotinylated otelixizumab was directly proportional to the availability of free otelixizumab binding sites.CD3/TCR complexes on CD4+ and CD8+ T cells were detected with a non-competing antibody. Changes in the MESF of TCR expression was a direct measurement of TCR modulation. Baseline assessments were carried out on the morning of Day 1, before the start of the first infusion of study drug. Change from Baseline was calculated by subtracting the Baseline value from the post-randomization value at Day 1, Day 4 and Day 8.
Time frame: Baseline (Pre-dose Day 1), Day 4, Day 8
This study was conducted at 85 centers in 9 countries namely Canada (4), Germany (3), Denmark (1), Spain (5), Finland (2), United Kingdom (4), Italy (8), Sweden (11) and United States of America (47) from 29 July 2008 to 31 January 2012. A total of 240 participants with new-onset Type 1 diabetes mellitus (NOT1DM) were planned to be enrolled.
| Milestone | Adolescent (Placebo) | Adolescent (Otelixizumab) | Adult (Placebo) | Adult (Otelixizumab) |
|---|---|---|---|---|
| Started | 10 | 19 | 81 | 162 |
| Completed | 10 | 19 | 72 | 153 |
| Not completed | 0 | 0 | 9 | 9 |
| Withdrew: Withdrawal by subject | 0 | 0 | 4 | 6 |
| Withdrew: Physician decision | 0 | 0 | 1 | 1 |
| Withdrew: Lost to follow-up | 0 | 0 | 3 | 2 |
| Withdrew: Other | 0 | 0 | 1 | 0 |
Mixed meal-stimulated C-peptide AUC was the area under the C-peptide/time curve from Time 0 to 120 minutes, calculated using the trapezoidal rule. This reported AUC was normalized for time interval by dividing it by 120 minutes. This normalized AUC was calculated for each participant at Baseline, Week 12, and at Months 6, 12, 18, and 24. Data has been presented for meal stimulated C-peptide Area under assessment performed at Month 12. Baseline assessments were carried out on the morning of Day 1, before the start of the first infusion of study drug. Change from Baseline was calculated by subtracting the Baseline value from the post-randomization value at Month 12.
| nanomoles per liter | Placebo | Otelixizumab |
|---|---|---|
| Change From Baseline in 2-hour Mixed Meal Stimulated C-peptide Area Under Curve [AUC] (Normalized for 120-minute Time Interval) at Month 12 | -0.21 ± 0.030 | -0.21 ± 0.021 |
A participant was considered a responder if, at the given time point, the participant had HbA1c\<= 6.5%, and mean daily insulin use over 7 consecutive days \< 0.5 international units per kilogram per day (IU/kg/day) during the 2 weeks preceding the visit. Data has been presented from number of participants with their percentages who were responders at Week 12 and Months 6 and 12.
| Participants | Placebo | Otelixizumab |
|---|---|---|
| Responders at Week 12 | 45 | 85 |
| Responders at Month 6 | 42 | 74 |
| Responders at Month 12 | 34 | 56 |
Participants recorded their daily insulin use in their electronic diaries. In particular, insulin was recorded thoroughly and accurately for at least 7 consecutive days during the 2 weeks before the visits at Baseline, Week 12, and Months 6 and 12. During each of these visits, the investigator/designee accessed the invivodata DiaryPRO web site to review insulin-use data for the previous 2-week period to ensure completeness. If errors/gaps were identified (e.g., if the participant did not take insulin and not entered 0 units), the investigator/designee recorded the missing data from participant recall using a data clarification form (DCF). Paper diary to collect insulin use, were reviewed for completeness. Any missing data that could be recalled by the participant was entered. If the participant did not record any insulin use during the 2-week period before the visit, the site obtained an insulin use history for the previous 7 days and calculated the average daily insulin dose.
| IU/kg | Placebo | Otelixizumab |
|---|---|---|
| Mean daily insulin use at Week 12 | 0.34 ± 0.017 | 0.31 ± 0.013 |
| Mean daily insulin use at Month 6 | 0.36 ± 0.022 | 0.36 ± 0.016 |
| Mean daily insulin use at Month 12 | 0.42 ± 0.023 | 0.39 ± 0.017 |
HbA1c levels were recorded at Screening, Baseline (Day 1), Day 28, Week 8, Week 12, Months 4 to 12 and Month 24. Data has been presented for HbA1c levels at Week 12 and Months 6 and 12.
| Percentage | Placebo | Otelixizumab |
|---|---|---|
| HbA1c levels at Month 12 | 6.83 ± 0.146 | 7.02 ± 0.108 |
| HbA1c levels at Month 6 | 6.60 ± 0.138 | 6.77 ± 0.100 |
| HbA1c levels at Week 12 | 6.45 ± 0.124 | 6.54 ± 0.094 |
Hypoglycemic events reported by participants were classified as defined by the American Diabetes Association (ADA) Workgroup on Hypoglycemia as follows: Severe hypoglycemia: an event requiring assistance of another person to actively administer carbohydrate, glucagon/other resuscitative actions, documented symptomatic hypoglycemia: an event during which typical symptoms of hypoglycemia are accompanied by a measured plasma glucose concentration(PGC)\<=70 mg/dL, asymptomatic hypoglycemia: an event not accompanied by typical symptoms of hypoglycemia but with a measured PGC\<=70 mg/dL,probable symptomatic hypoglycemia: an event during which symptoms of hypoglycemia are not accompanied by a plasma glucose determination, but were presumably caused by a PGC\<=70 mg/dL and relative hypoglycemia: an event during which the person with diabetes reports any of the typical symptoms of hypoglycemia, and interprets the symptoms as indicative of hypoglycemia, but with a measured PGC\>70 mg/dL.
| Hypoglycemic events | Placebo | Otelixizumab |
|---|---|---|
| Severe hypoglycemia upto Month 12 | 2 | 5 |
| Documented symptomatic hypoglycemia upto Month 12 | 3092 | 6322 |
| Asymptomatic hypoglycemia upto Month 12 | 4718 | 9962 |
| Probable symptomatic hypoglycemia upto Month 12 | 84 | 93 |
| Relative hypoglycemia upto Month 12 | 85 | 211 |
Hypoglycemic events reported by participants were classified as defined by the ADA Workgroup on Hypoglycemia as Severe hypoglycemia: an event requiring assistance of another person to actively administer carbohydrate, glucagon/other resuscitative actions, documented symptomatic hypoglycemia: an event during which typical symptoms of hypoglycemia are accompanied by a measured plasma glucose concentration (PGC)\<=70 mg/dL, asymptomatic hypoglycemia: an event not accompanied by typical symptoms of hypoglycemia but with a measured PGC\<=70 mg/dL,probable symptomatic hypoglycemia: an event during which symptoms of hypoglycemia are not accompanied by a plasma glucose determination, but were presumably caused by a PGC\<=70 mg/dL and relative hypoglycemia: an event during which the person with diabetes reports any of the typical symptoms of hypoglycemia, and interprets the symptoms as indicative of hypoglycemia, but with a measured PGC\>70 mg/dL. Only categories with values are presented.
| Participants | Placebo | Otelixizumab |
|---|---|---|
| Severe hypoglycemia upto Month 12 | 2 | 4 |
| Documented symptomatic hypoglycemia upto Month 12 | 78 | 163 |
| Asymptomatic hypoglycemia upto Month 12 | 10 | 13 |
The event frequency of glucose measurements that were hypoglycemic excursions were calculated per participant basis, using the number of occurrences where blood glucose was less than or equal to 70 mg/dL. Most complete glucose interval was the 7 day period with the maximum number of days with at least 4 recordings per day. If these results were in more than one 7 day period, then the 7 day period with the largest average number of daily recordings (out of those with the maximum number of days with at least 4 recordings per day) was selected. If there were 2 or more 7 day periods that have the same number of days with at least 4 recordings and the same maximum average number of glucose recordings, the period that ended closest to the day of the study was selected.
| Hypoglycemic excursions | Placebo | Otelixizumab |
|---|---|---|
| Number of hypoglycemic excursions at Week 12 | 2.3 ± 0.28 | 2.8 ± 0.27 |
| Number of hypoglycemic excursions at Month 6 | 3.0 ± 0.36 | 2.9 ± 0.27 |
| Number of hypoglycemic excursions at Month 12 | 2.9 ± 0.41 | 3.2 ± 0.32 |
The greatest hypoglycemic excursions during an interval was calculated as 70 mg/dL minus the lowest recorded glucose level in the interval. If a participant had data recorded during the interval but did not have a value below 70 mg/dL, the participants greatest hypoglycemic excursion for that interval was 0 mg/dL. Most complete glucose interval was the 7 day period with the maximum number of days with at least 4 recordings per day. If these results were in more than one 7 day period, then the 7 day period with the largest average number of daily recordings (out of those with the maximum number of days with at least 4 recordings per day) was selected. If there were 2 or more 7 day periods that have the same number of days with at least 4 recordings and the same maximum average number of glucose recordings, the period that ended closest to the day of the study was selected.
| milligrams per deciliter | Placebo | Otelixizumab |
|---|---|---|
| Magnitude of excursion, Week 12 | 9.4 ± 0.92 | 10.8 ± 0.90 |
| Magnitude of excursion, Month 6 | 11.9 ± 1.24 | 10.6 ± 0.77 |
| Magnitude of excursion, Month 12 | 11.2 ± 1.20 | 11.0 ± 0.92 |
Percentage of hypoglycemic excursions was calculated as the total number of observations that exceed the hypoglycemic excursion boundary (i.e.\<= 70 mg/dL) divided by the total number of glucose measurements recorded in a time interval for the intervals: Baseline to Week 12, post-Week 12 to Month 6, post-Month 6 to Month 12. Most complete glucose interval was the 7 day period with the maximum number of days with at least 4 recordings per day. If these results were in more than one 7 day period, then the 7 day period with the largest average number of daily recordings (out of those with the maximum number of days with at least 4 recordings per day) was selected. If there were 2 or more 7 day periods that have the same number of days with at least 4 recordings and the same maximum average number of glucose recordings, the period that ended closest to the day of the study was selected. Data has been presented for number of participants with their percentages having hypoglycemic excursion.
| Participants | Placebo | Otelixizumab |
|---|---|---|
| Percentage of participants with excursion,Week 12 | 72 | 127 |
| Percentage of participants with excursion,Month 6 | 57 | 121 |
| Percentage of participants with excursion,Month 12 | 56 | 111 |
The event frequency of glucose measurements that were hyperglycemic excursions were calculated on a per participant basis using the number of occurrences where blood glucose was greater than the hyperglycemic tolerance limit. There were 3 hyperglycemic tolerance limits considered: 200 mg/dL, 130 mg/dL and 100 mg/dL. Most complete glucose interval was the 7 day period with the maximum number of days with at least 4 recordings per day. If these results were in more than one 7 day period, then the 7 day period with the largest average number of daily recordings (out of those with the maximum number of days with at least 4 recordings per day) was selected. If there were 2 or more 7 day periods that have the same number of days with at least 4 recordings and the same maximum average number of glucose recordings, the period that ended closest to the day of the study was selected.
| Hyperglycemic excursions | Placebo | Otelixizumab |
|---|---|---|
| Threshold > 100 mg/dL at Week 12 | 34.0 ± 1.78 | 32.9 ± 1.15 |
| Threshold > 130 mg/dL at Week 12 | 20.5 ± 1.72 | 19.9 ± 1.01 |
| Threshold > 200 mg/dL at Week 12 | 5.7 ± 0.85 | 5.6 ± 0.59 |
| Threshold > 100 mg/dL at Month 6 | 33.5 ± 1.77 | 35.1 ± 1.41 |
| Threshold > 130 mg/dL at Month 6 | 20.8 ± 1.68 | 22.7 ± 1.25 |
| Threshold > 200 mg/dL at Month 6 | 6.5 ± 1.07 | 7.9 ± 0.85 |
| Threshold > 100 mg/dL at Month 12 | 35.6 ± 1.97 | 33.4 ± 1.27 |
| Threshold > 130 mg/dL at Month 12 | 24.0 ± 1.92 | 22.2 ± 1.05 |
| Threshold > 200 mg/dL at Month 12 | 8.6 ± 1.42 | 6.9 ± 0.59 |
The greatest hyperglycemic excursions during an interval was calculated as the largest recorded glucose level in the interval minus the hyperglycemic tolerance limit value (HGTLV). If a participant had data recorded during the interval but did not have a value above the HGTLV, the participants greatest hyperglycemic excursion for that interval was 0 mg/dL. Most complete glucose interval was the 7 day period with the maximum number of days with at least 4 recordings per day. If these results were in more than one 7 day period, then the 7 day period with the largest average number of daily recordings (out of those with the maximum number of days with at least 4 recordings per day) was selected. If there were 2 or more 7 day periods that have the same number of days with at least 4 recordings and the same maximum average number of glucose recordings, the period that ended closest to the day of the study was selected.
| milligrams per deciliter | Placebo | Otelixizumab |
|---|---|---|
| Threshold> 100 mg/dL at Week 12 | 158.3 ± 9.26 | 158.4 ± 6.65 |
| Threshold> 130 mg/dL at Week 12 | 128.3 ± 9.26 | 128.4 ± 6.65 |
| Threshold> 200 mg/dL at Week 12 | 65.7 ± 8.51 | 65.7 ± 6.12 |
| Threshold> 100 mg/dL at Month 6 | 154.6 ± 9.34 | 175.7 ± 8.09 |
| Threshold> 130 mg/dL at Month 6 | 124.8 ± 9.31 | 145.7 ± 8.09 |
| Threshold> 200 mg/dL at Month 6 | 63.3 ± 8.32 | 80.1 ± 7.75 |
| Threshold> 100 mg/dL at Month 12 | 176.7 ± 10.02 | 177.5 ± 7.08 |
| Threshold> 130 mg/dL at Month 12 | 146.8 ± 10.00 | 147.5 ± 7.07 |
| Threshold> 200 mg/dL at Month 12 | 81.8 ± 9.33 | 82.6 ± 6.61 |
Percentage of hyperglycemic excursions was calculated as the total number of observations that exceed the hyperglycemic excursion boundary (i.e. \> HGTLV) divided by the total number of glucose measurements recorded in a time interval for the intervals: Baseline to Week 12, post-Week 12 to Month 6, post-Month 6 to Month 12. Most complete glucose interval was the 7 day period with the maximum number of days with at least 4 recordings per day. If these results were in more than one 7 day period, then the 7 day period with the largest average number of daily recordings (out of those with the maximum number of days with at least 4 recordings per day) was selected. If there were 2 or more 7 day periods that have the same number of days with at least 4 recordings and the same maximum average number of glucose recordings, the period that ended closest to the day of the study was selected. Data for number of participants with their percentages are presented.
| Participants | Placebo | Otelixizumab |
|---|---|---|
| Threshold> 100 mg/dL at Week 12 | 90 | 177 |
| Threshold> 130 mg/dL at Week 12 | 90 | 177 |
| Threshold> 200 mg/dL at Week 12 | 65 | 130 |
| Threshold> 100 mg/dL at Month 6 | 80 | 166 |
| Threshold> 130 mg/dL at Month 6 | 79 | 166 |
| Threshold> 200 mg/dL at Month 6 | 57 | 139 |
| Threshold> 100 mg/dL at Month 12 | 78 | 161 |
| Threshold> 130 mg/dL at Month 12 | 77 | 160 |
| Threshold> 200 mg/dL at Month 12 | 60 | 131 |
Average daily risk range is a measure for evaluation of blood glucose variability that was designed to be equally sensitive to hypoglycemia and hyperglycemia. The ADRR was assessed over 30-day periods prior to Baseline and at key visits Week 12 and Months 6 and 12. Baseline assessments were carried out on the morning of Day 1, before the start of the first infusion of study drug. Change from Baseline was calculated by subtracting the Baseline value from the post-randomization value at Week 12 and Months 6 and 12.
| Ratio | Placebo | Otelixizumab |
|---|---|---|
| ADRR at Week 12 | -0.41 ± 0.826 | 0.71 ± 0.599 |
| ADRR at Month 6 | 2.03 ± 1.133 | 2.86 ± 0.801 |
| ADRR at Month 12 | 3.29 ± 1.038 | 4.22 ± 0.732 |
O'Brien mean rank analyses was performed on a two-part composite of the baseline-adjusted HbA1c level and the baseline-adjusted mean total daily insulin use per kg body weight in the otelixizumab group compared with the placebo group at Months 6, 12. For the O'Brien mean rank analysis at a particular time point, adjusted HbA1c values (for both treatment groups together) was ranked from smallest to largest, and adjusted mean daily insulin use values were ranked from smallest to largest. For each participant, the HbA1c and insulin use ranks were added together, producing a composite rank. A treatment comparison test was then performed on the composite ranks.
| Composite rank score | Placebo | Otelixizumab |
|---|---|---|
| Composite rank summary, Month 6 | 238 ± 123.3 | 247 ± 113.7 |
| Composite rank summary, Month 12 | 245 ± 120.0 | 244 ± 115.2 |
O'Brien analyses will be performed on a three-part composite of HbA1c level, C-peptide AUC, and mean daily Insulin use in the otelixizumab group compared with the placebo group at Months 6 and12. For the O'Brien mean rank analysis at a particular time point, HbA1c and insulin use will be ranked from smallest to largest, and C-peptide AUC will be ranked from largest to smallest. For each participant, the C-Peptide AUC, ranks for HbA1c and insulin use were added together, producing a composite rank. A treatment comparison test was then performed on the composite ranks.
| Composite rank score | Placebo | Otelixizumab |
|---|---|---|
| Month 6 | 365 ± 83.8 | 373 ± 105.6 |
| Month 12 | 360 ± 85.1 | 366 ± 95.4 |
Levels of cytokine (TNFα, IL-6, IL-10) were measured at Baseline and at 2 hours after end of infusion (EOI) on Day 1, Day 4, Day 8 . Baseline assessments were carried out on the morning of Day 1, before the start of the first infusion of study drug. Change from Baseline was calculated by subtracting the Baseline value from the post-randomization value at Day 1, Day 4 and Day 8.
| picograms per milliliter | Placebo | Otelixizumab |
|---|---|---|
| IL-6 levels, Day 1, 2 hours after EOI | 0.76 ± 0.680 | 2.78 ± 0.544 |
| IL-6 levels, Day 4, 2 hours after EOI | -0.13 ± 0.251 | 3.01 ± 1.107 |
| IL-6 levels, Day 8, 2 hours after EOI | 0.45 ± 0.448 | 14.59 ± 5.266 |
| IL-10 levels, Day 1, 2 hours after EOI | 0.15 ± 0.342 | 4.61 ± 1.770 |
| IL-10 levels, Day 4, 2 hours after EOI | 0.55 ± 0.629 | 1.35 ± 0.575 |
| IL-10 levels, Day 8, 2 hours after EOI | 1.84 ± 1.019 | 25.57 ± 7.196 |
| TNF-a levels, Day 1, 2 hours after EOI | -0.126 ± 0.0719 | 2.320 ± 0.3996 |
| TNF-a levels, Day 4, 2 hours after EOI | 0.111 ± 0.2381 | 1.509 ± 0.5740 |
| TNF-a levels, Day 8, 2 hours after EOI | 0.135 ± 0.2649 | 3.614 ± 0.8920 |
Blood samples were drawn for lymphocyte subset evaluations at Baseline and at 2hours after EOI on Day 4, pre-dose and after E0I on Day 8, Day 14, Day 21, Day 28, Week 6, Week 8, Week 10, Week 12, Month 6 and Month 12. Percentages of relevant lymphocyte subsets were determined by flow cytometry. The lymphocyte subsets assessed included CD8+CD25+ T lymphocytes, as well as the subsets of lymphocytes of these type that were positive for FoxP3, a protein that was expressed at high levels in the cytoplasm of regulatory T cells. CD4+CD25hiFoxP3+ T lymphocytes, a cell type was of interest because it played a regulatory role in T1DM. Baseline assessments were carried out on the morning of Day 1, before the start of the first infusion of study drug. Change from Baseline was calculated by subtracting the Baseline value from the post-randomization value at the time of assessment.
| Percent change | Placebo | Otelixizumab |
|---|---|---|
| CD4+CD25+FoxP3+ T, Day 4, 2 hours after EOI | 118.8 (32.1 to 366.9) | 53.4 (3.4 to 235.9) |
| CD4+CD25+FoxP3+ T, Day 8 pre-dose | 94.4 (25.9 to 199.9) | 49.7 (9.4 to 148.5) |
| CD4+CD25+FoxP3+ T, Day 8, 2 hours after EOI | 113.2 (28.8 to 2127.6) | 40.1 (2.1 to 3737.0) |
| CD4+CD25+FoxP3+ T, Day 14 | 114.5 (26.5 to 2384.4) | 101.3 (15.5 to 10906.4) |
| CD4+CD25+FoxP3+ T, Day 21 | 114.6 (34.8 to 489.8) | 101.9 (0.0 to 44228.1) |
| CD4+CD25+FoxP3+ T, Day 28 | 95.1 (7.0 to 1612.7) | 101.7 (2.1 to 6363.7) |
| CD4+CD25+FoxP3+ T, Week 6 | 104.1 (0.0 to 514.2) | 106.6 (0.0 to 7010.9) |
| CD4+CD25+FoxP3+ T, Week 8 | 110.1 (29.1 to 1602.3) | 107.1 (4.7 to 15806.4) |
| CD4+CD25+FoxP3+ T, Week 10 | 109.9 (8.6 to 1820.9) | 102.7 (7.4 to 9943.6) |
| CD4+CD25+FoxP3+ T, Week 12 | 102.5 (9.8 to 1018.7) | 85.5 (2.9 to 9911.7) |
| CD4+CD25+FoxP3+ T, Month 6 | 137.9 (19.5 to 1409.6) | 133.3 (19.8 to 10357.4) |
| CD4+CD25+FoxP3+ T, Month 12 | 122.0 (9.5 to 628.7) | 106.9 (0.4 to 31690.3) |
| CD4+CD25hiFoxP3+ T Cells, Day 4, 2 hours after EOI | 151.9 (12.6 to 400.8) | 60.8 (1.5 to 364.5) |
| CD4+CD25hiFoxP3+ T Cells, Day 8 pre-dose | 93.8 (13.6 to 521.7) | 43.5 (3.6 to 675.0) |
| CD4+CD25hiFoxP3+ T Cells, Day 8, 2 hours after EOI | 110.7 (18.6 to 3577.8) | 35.9 (0.0 to 321279) |
| CD4+CD25hiFoxP3+ T Cells, Day 14 | 118.4 (8.8 to 1502.5) | 109.7 (5.8 to 1364664) |
| CD4+CD25hiFoxP3+ T Cells, Day 21 | 110.0 (9.7 to 1720.2) | 98.8 (0.0 to 1479653) |
| CD4+CD25hiFoxP3+ T Cells, Day 28 | 101.1 (2.1 to 949.9) | 108.7 (0.0 to 62190.9) |
| CD4+CD25hiFoxP3+ T Cells, Week 6 | 106.9 (0.0 to 2508.7) | 110.7 (0.0 to 9573.5) |
| CD4+CD25hiFoxP3+ T Cells, Week 8 | 131.7 (14.1 to 843.2) | 120.3 (0.5 to 175040) |
| CD4+CD25hiFoxP3+ T Cells, Week 10 | 97.7 (1.5 to 2356.8) | 107.0 (0.0 to 128591) |
| CD4+CD25hiFoxP3+ T Cells, Week 12 | 113.6 (1.9 to 1310.2) | 90.9 (0.1 to 1045228) |
| CD4+CD25hiFoxP3+ T Cells, Month 6 | 150.9 (6.1 to 25639.5) | 153.2 (5.5 to 1544544) |
| CD4+CD25hiFoxP3+ T Cells, Month 12 | 166.4 (5.1 to 1748.9) | 160.6 (0.0 to 78843.4) |
The amount of cell-bound otelixizumab was determined by flow cytometry. The extent of T cell receptor alpha beta (TCRαβ) expression was determined using an antibody that bound to TCRαβ but did not compete with otelixizumab for binding sites at the expected range of concentrations. The MESF of the anti-TCRαβ antibody was used to quantify the number of CD3/TCR complexes present on T cells. Free otelixizumab binding sites (sites not occupied by otelixizumab) were detected by staining with biotinylated otelixizumab. The MESF of bound biotinylated otelixizumab was directly proportional to the availability of free otelixizumab binding sites. MESF of bound antibody on CD4+ T cells was a direct measurement of cell-bound otelixizumab on CD4+ T cells. Baseline assessments were carried out on the morning of Day 1, before the start of the first infusion of study drug. Change from Baseline was calculated by subtracting the Baseline value from the post-randomization value at Day 1, Day 4 and Day 8.
| Percent change | Placebo | Otelixizumab |
|---|---|---|
| CD4+ T cells, Day 1, 2 hours after EOI | 125.1 ± 18.00 | 914.8 ± 269.18 |
| CD4+ T cells, Day 4, 2 hours after EOI | 174.3 ± 41.95 | 2719.8 ± 369.41 |
| CD4+ T cells, Day 8, pre-dose | 151.5 ± 39.49 | 471.5 ± 98.53 |
| CD4+ T cells, Day 8, 2 hours after EOI | 167.9 ± 47.67 | 1387.5 ± 274.21 |
The extent of saturation of CD3/TCR receptors on CD4+ and CD8+ lymphocytes was determined by flow cytometry. The extent of TCRαβ expression was determined using an antibody that bound to TCRαβ but did not compete with otelixizumab for binding sites at the expected range of concentrations. The MESF of the anti-TCRαβ antibody was used to quantify the number of CD3/TCR complexes present on T cells. The MESF of bound biotinylated otelixizumab was directly proportional to the availability of free otelixizumab binding sites. MESF of free CD3 sites on CD4+ T cells and CD8+ T cells was direct measurement of saturation of the CD3/TCR complex on CD4+ T cells and CD8+ T cells. Baseline assessments were carried out on the morning of Day 1, before the start of the first infusion of study drug. Change from Baseline was calculated by subtracting the Baseline value from the post-randomization value at Day 1, Day 4 and Day 8.
| Percent change | Placebo | Otelixizumab |
|---|---|---|
| CD4+ T cells, Day 1, 2 hours after EOI | 93.4 ± 2.40 | 90.9 ± 3.82 |
| CD4+ T cells, Day 4, 2 hours after EOI | 109.7 ± 11.91 | 50.2 ± 4.90 |
| CD4+ T cells, Day 8, pre-dose | 97.7 ± 10.66 | 59.0 ± 5.31 |
| CD4+ T cells, Day 8, 2 hours after EOI | 98.0 ± 13.03 | 21.7 ± 3.33 |
| CD8+ T cells, Day 1, 2 hours after EOI | 92.4 ± 2.38 | 91.4 ± 3.82 |
| CD8+ T cells, Day 4, 2 hours after EOI | 116.7 ± 14.53 | 51.6 ± 5.23 |
| CD8+ T cells, Day 8, pre-dose | 97.4 ± 11.84 | 60.8 ± 6.11 |
| CD8+ T cells, Day 8, 2 hours after EOI | 98.2 ± 14.63 | 23.0 ± 3.72 |
The extent of modulation of CD3/TCR receptors on CD4+ and CD8+ lymphocytes was determined by flow cytometry. The extent of TCRαβ expression was determined using an antibody that bound to TCRαβ but did not compete with otelixizumab for binding sites at the expected range of concentrations. The MESF of the anti-TCRαβ antibody was used to quantify the number of CD3/TCR complexes present on T cells. The MESF of bound biotinylated otelixizumab was directly proportional to the availability of free otelixizumab binding sites.CD3/TCR complexes on CD4+ and CD8+ T cells were detected with a non-competing antibody. Changes in the MESF of TCR expression was a direct measurement of TCR modulation. Baseline assessments were carried out on the morning of Day 1, before the start of the first infusion of study drug. Change from Baseline was calculated by subtracting the Baseline value from the post-randomization value at Day 1, Day 4 and Day 8.
| Percent change | Placebo | Otelixizumab |
|---|---|---|
| CD4+ T cells, Day 1, 2 hours after EOI | 94.2 ± 2.95 | 91.1 ± 2.90 |
| CD4+ T cells, Day 4, 2 hours after EOI | 103.8 ± 8.93 | 70.8 ± 3.89 |
| CD4+ T cells, Day 8, pre-dose | 101.4 ± 6.09 | 61.0 ± 2.65 |
| CD4+ T cells, Day 8, 2 hours after EOI | 103.4 ± 5.87 | 32.2 ± 2.52 |
| CD8+ T cells, Day 1, 2 hours after EOI | 95.2 ± 2.72 | 93.7 ± 3.06 |
| CD8+ T cells, Day 4, 2 hours after EOI | 111.1 ± 10.56 | 77.1 ± 4.33 |
| CD8+ T cells, Day 8, pre-dose | 101.8 ± 6.19 | 62.3 ± 2.68 |
| CD8+ T cells, Day 8, 2 hours after EOI | 103.0 ± 6.05 | 36.2 ± 2.52 |
Collected over Upto Month 24. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/91 (0%) | 6/91 (6.6%) | 81/91 (89%) |
| Otelixizumab | 0/181 (0%) | 15/181 (8.3%) | 173/181 (95.6%) |
| Event | Placebo | Otelixizumab |
|---|---|---|
| Cytokine release syndromeImmune system disorders | 0/91 | 3/181 |
| AppendicitisInfections and infestations | 1/91 | 0/181 |
| Gastroenteritis viralInfections and infestations | 1/91 | 0/181 |
| TonsillitisInfections and infestations | 1/91 | 0/181 |
| Viral upper respiratory tract infectionInfections and infestations | 1/91 | 0/181 |
| Neurological symptomNervous system disorders | 1/91 | 0/181 |
| Major depressionPsychiatric disorders | 1/91 | 0/181 |
| CholelithiasisHepatobiliary disorders | 1/91 | 0/181 |
| Anal abscessInfections and infestations | 0/91 | 1/181 |
| Septic embolusInfections and infestations | 0/91 | 1/181 |
| Event | Placebo | Otelixizumab |
|---|---|---|
| HeadacheNervous system disorders | 45/91 | 155/181 |
| NauseaGastrointestinal disorders | 20/91 | 60/181 |
| NasopharyngitisInfections and infestations | 29/91 | 48/181 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 24/91 | 25/181 |
| FatigueGeneral disorders | 20/91 | 42/181 |
| VomitingGastrointestinal disorders | 13/91 | 35/181 |
| PyrexiaGeneral disorders | 10/91 | 34/181 |
| MyalgiaMusculoskeletal and connective tissue disorders | 14/91 | 21/181 |
| LymphadenopathyBlood and lymphatic system disorders | 13/91 | 18/181 |
| ChillsGeneral disorders | 6/91 | 24/181 |
| Age, Continuous(Years) | Placebo | Otelixizumab | Total |
|---|---|---|---|
| Mean | 25.2 ± 7.13 | 24.7 ± 6.54 | 24.9 ± 6.73 |
| Sex: Female, Male(Participants) | Placebo | Otelixizumab | Total |
|---|---|---|---|
| Female | 31 | 64 | 95 |
| Male | 60 | 117 | 177 |
| Race (NIH/OMB)(Participants) | Placebo | Otelixizumab | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 1 |
| Asian | 2 | 1 | 3 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 2 | 6 | 8 |
| White | 85 | 169 | 254 |
| More than one race | 2 | 4 | 6 |
| Unknown or Not Reported | 0 | 0 | 0 |
Showing the first 100 of 109 sites across 9 countries.
This study is completed, as verified in Jul 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
GlaxoSmithKline